Astellas’ Veoza™ (fezolinetant) now available in Ireland for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause
Fezolinetant is a first-in-class selective neurokinin 3 receptor antagonist providing a nonhormonal option to reduce moderate to severe VMS associated ...